BioSpace News Archive

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock.

Net income of $1.2 million driven by 6.7% revenue growth from prior year period and 18.3% operating margin

The Miller Children’s Hospital Long Beach Auxiliary pledged $500,000 to support an adolescent rehabilitation gym in the future Cherese Mari Laulhere Children’s Village at MemorialCare Miller Children’s & Women’s Hospital Long Beach.

The Board of Directors of Zoetis Inc. has declared a second quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share.

FibroGen, Inc. announced that the U.S. Food and Drug Administration has completed its filing review of its New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease, in both non-dialysis-dependent and dialysis-dependent patients.

CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease

New Jersey’s life sciences community came out for BioNJ’s 27th Annual Dinner Meeting & Innovation Celebration that took place last Thursday, February 6, at the Hilton East Brunswick.

Eli Lilly and Company and Incyte announced that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis.

PDS Biotechnology Corporation, a clinical-stage immuno-oncology company developing multiple therapies based on PDS Biotechnology’s proprietary Versamune® T-cell activating technology, announced the pricing of an underwritten public offering consisting of 9,230,770 shares of common stock at a price to the public of $1.30 per share.

Dr. David L. Pfeifer recognized by the American College of Prosthodontists Education Foundation.